Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Genprex ( (GNPX) ) is now available.
On May 7, 2025, Genprex announced a new Sponsored Research Agreement with the University of Pittsburgh to conduct preclinical studies on GPX-002, a gene therapy for Type 1 and Type 2 diabetes. The preclinical data showed promising results, with significant decreases in insulin requirements and improvements in glucose tolerance in animal models, suggesting GPX-002 could be a groundbreaking treatment for diabetes.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for diabetes and cancer. The company is known for its innovative approaches to treating Type 1 and Type 2 diabetes, utilizing gene therapy constructs to potentially transform treatment paradigms.
Average Trading Volume: 4,746,807
Technical Sentiment Signal: Sell
Current Market Cap: $7.06M
For an in-depth examination of GNPX stock, go to TipRanks’ Stock Analysis page.